AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.
- CDMO Selection: Start With The Relationship, Not The RFP
- Why FAT Should Confirm Alignment, Not Reveal Its Absence
- What Reliance, Annex 1, And AI Mean For The Future Of GMP
- Applying Contamination Control By Design: A Practical Guide For CDMOs
- What To Do About Process Drift In Your Biosimilar's Reference Product
- Field Notes: Freeing Process Data For Automation At Kivi Bio AI Summit
- Rethinking CQV In A Digital, Agile Manufacturing Landscape
GUEST COLUMNISTS
-
CDMO Selection: Start With The Relationship, Not The RFP
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
-
Why FAT Should Confirm Alignment, Not Reveal Its Absence
In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration test of the entire project. That is a problem. Here's how to flip that mindset.
-
What Reliance, Annex 1, And AI Mean For The Future Of GMP
EMA’s Brendan Cuddy explains how regulators are adapting oversight to global supply chains, new technologies, and growing operational complexity.
-
Applying Contamination Control By Design: A Practical Guide For CDMOs
This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and more.
-
What To Do About Process Drift In Your Biosimilar's Reference Product
Biosimilar development often reveals quality drifts in certain lots of the reference biologic. In most cases, quality changes are noncritical, but some drifts can impact CQAs.
-
Field Notes: Freeing Process Data For Automation At Kivi Bio AI Summit
The missing link between data generation and unleashing it to power automation often lies in well-governed cloud infrastructure.
-
Rethinking CQV In A Digital, Agile Manufacturing Landscape
While commissioning, qualification, and validation (CQV) remains foundational, the way it is planned and executed must evolve to keep pace with modern manufacturing realities.
BIOSIMILAR WHITE PAPERS
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies4/17/2026
Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Aseptic Process Design And Simulation Under Annex 1 Guidelines1/9/2026
Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.
BIOSIMILAR APP NOTES & CASE STUDIES
- Non Animal Origin Squalene For High-Risk Applications
- Media And Buffer Mixing Using The Xcellerex™ Magnetic Mixer
- Monitoring Bioprocesses In A Light Environment Using Raman Spectroscopy
- Aseptic Filling Solution Enhances Sterility Assurance for Pharma Manufacturer
- Assessing Particle Generation In A Single-Use Mixing System
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Chime Biologics And Daewoong Pharmaceutical Enter Strategic Partnership To Advance Dupilumab Biosimilar Development And Commercialization In Global Markets
- USP Publishes Product-Specific Emerging Biologics Standards For Public Comment
- Henlius' Pertuzumab Approved In China, Solidifying Breast Cancer Strategy As The First China-US-EU Approved Chinese Trastuzumab-Pertuzumab Combination
- Boan Biotech Submits A Biologics License Application For Two Denosumab Biosimilars In The U.S.
- Samsung Bioepis Launches OPUVIZ (Aflibercept) 40 mg/mL Vial Across Europe, To Treat Ophthalmic Conditions
- Globalisation 2.0 | First Patient Dosed In China For International Multi-Centre Phase 1 Clinical Trial Of Henlius' Subcutaneous Daratumumab Biosimilar HLX15-SC
- Polpharma Biologics And Tuteur Sign Licensing Agreement For A Biosimilar For Autoimmune Diseases
- Mabwell Announces NMPA Approval Of Supplemental Application For Additional Indications Of MAIWEIJIAN (Denosumab Injection)
NEWSLETTER ARCHIVE
- 06.04.26 -- Are Biotechs Wasting Time On The Wrong CDMO?
- 05.21.26 -- Minimizing Regulatory Risk For Biologics Manufacturing Changes
- 05.14.26 -- Do Changes Signal The End Of Biosimilar Regulatory Redundancy?
- 05.07.26 -- The Business Case For Continuous Manufacturing In Biologics
- 04.30.26 -- Quantifying Single-Use Waste Produced During mAb Manufacture